$TMDX earnings report

TransMedics Reports Third Quarter 2026 Financial Results Strong Revenue Generation Drives Increase in Full-Year 2026 Guidance; Recent Progress Positions Company for Continued Growth with Several Near- and Mid-Term Catalysts. AlphAI read TransMedics Group's Third Quarter 2026 filing as solid. 2 quarters are on record below.

Third Quarter 2026

AlphAI · Earnings readTMDX · Third Quarter 2026 · ended September 30, 2026

TransMedics Reports Third Quarter 2026 Financial Results Strong Revenue Generation Drives Increase in Full-Year 2026 Guidance; Recent Progress Positions Company for Continued Growth with Several Near- and Mid-Term Catalysts

✓Solid quarter

Third-quarter revenue grew 41% to $203.0 million, supported by Liver and Heart National OCS Program volume, logistics services and PAD Aviation. Profitability remained positive but gross margin and operating margin declined, while net income and diluted EPS fell year over year. The company raised full-year revenue guidance.

Revenue
$203M
41% y/y
Net product revenue, three months ended September 30, 2026
$113M
29% y/y
Gross margin · GAAP
58.5%
EPS · GAAP
$0.46
-30% y/y
FY 2026 outlook
$764-$774 million

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenue, three months ended September 30, 2026GAAP$203.0M–41%
Organic revenue, three months ended September 30, 2026non-GAAP$193.6M–34.6%
Gross profit, three months ended September 30, 2026GAAP$118.7M––
Gross margin, three months ended September 30, 2026GAAP58.5%––
Research, development and clinical trials expense, three months ended September 30, 2026GAAP$29.18M––
Selling, general and administrative expense, three months ended September 30, 2026GAAP$61.33M––
Total operating expenses, three months ended September 30, 2026GAAP$90.52M––
Stock compensation expense, three months ended September 30, 2026GAAP$12.1M––
Income from operations, three months ended September 30, 2026GAAP$28.14M–21%
Operating margin, three months ended September 30, 2026GAAP13.9%–-230bps
Adjusted income from operations, three months ended September 30, 2026non-GAAP$28.87M–22%
Adjusted operating margin, three months ended September 30, 2026non-GAAP14.2%–-220bps
Interest expense, three months ended September 30, 2026GAAP−$7.27M––
Income before income taxes, three months ended September 30, 2026GAAP$24.10M––
Net income, three months ended September 30, 2026GAAP$17.07M––
Diluted net income per share, three months ended September 30, 2026GAAP$0.46–-30%
Adjusted net income, three months ended September 30, 2026non-GAAP$18.91M––
Adjusted diluted net income per common share, three months ended September 30, 2026non-GAAP$0.51–-24%
Total revenue, nine months ended September 30, 2026GAAP$566.9M–27%
Income from operations, nine months ended September 30, 2026GAAP$65.17M–-25%
Operating margin, nine months ended September 30, 2026GAAP11.5%–-810bps
Adjusted income from operations, nine months ended September 30, 2026non-GAAP$72.77M–-19%
Adjusted operating margin, nine months ended September 30, 2026non-GAAP12.8%–-740bps
Net income, nine months ended September 30, 2026GAAP$39.07M––
Diluted net income per share, nine months ended September 30, 2026GAAP$1.08–-53%
Adjusted net income, nine months ended September 30, 2026non-GAAP$46.04M––
Adjusted diluted net income per common share, nine months ended September 30, 2026non-GAAP$1.26–-46%

Segments

SegmentRevenueq/qy/y
Net product revenue, three months ended September 30, 2026The release attributed total revenue growth primarily to increasing Liver and Heart volume through the National OCS Program.$113.4M–29%
Service revenue, three months ended September 30, 2026Growth included additional revenue from TransMedics logistics services and the contribution of PAD Aviation following the Company's strategic investment on July 1, 2026.$89.6M–60%
Organic service revenue, three months ended September 30, 2026This non-GAAP measure excludes $9,385 (in thousands) of PAD Aviation charter services.$80.20M–42.8%

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

FY 2026 outlook

  • Revenue$764-$774 million
  • NoteFY 2026 Revenue (excluding PAD Aviation): $750-$760 million
  • NoteFY 2026 Revenue (including PAD Aviation) implied annual growth compared to FY 2025 revenue: 26% to 28%
  • NoteFY 2026 Revenue (excluding PAD Aviation) implied annual growth compared to FY 2025 revenue: 24% to 26%
  • NoteExpected PAD Aviation revenue: approximately $14 million

What drove it

  • Increasing Liver and Heart volume through the National OCS Program.
  • Additional revenue generated by TransMedics logistics services.
  • Contribution of PAD Aviation following the Company's strategic investment on July 1, 2026.
  • Reduced scrap, lower inventory adjustments and logistics efficiencies resulting from pricing improvements across service and logistics operations.
  • Productivity gains from reduced supplemental lift utilization, lower ground transportation cost per mission, and improved leverage of fixed operating costs as volume increased.
  • Completed enrollment in Part A of the Next-Generation OCS ENHANCE Heart trial and FDA approval of a continued access protocol allowing enrollment of an additional 90 patients.
  • FDA IDE approvals for ENHANCE Heart Part B and DENOVO Lung trials, including CHOPS as a control arm for both trials.
  • First European transplant logistics tender awarded in Italy.

Concerns

  • Gross margin was 58.5%, compared with 58.8% in the prior-year period, primarily reflecting a higher mix of service revenue.
  • Operating margin was 13.9%, compared with 16.2% in the prior-year period.
  • Net income was $17.1 million, compared with $24.3 million in the prior-year period.
  • Diluted net income per share was $0.46, compared with $0.66 in the prior-year period.
  • Operating expenses increased to $90.5 million from $61.3 million, driven by planned investment in OCS Kidney, Next-Generation OCS and ENHANCE clinical programs, headcount and infrastructure investments.
  • Interest expense was $(7,271) (in thousands), compared with $(3,491) (in thousands) in the prior-year period.
  • The company disclosed that it has identified a material weakness in its internal control over financial reporting.

What to watch

  • ENHANCE Heart Part B and DENOVO Lung trial progress following October FDA IDE approvals.
  • OCS NOP launches planned in Italy, the Netherlands and Belgium.
  • Execution of the first European transplant logistics tender in Italy.
  • OCS Kidney first-in-human clinical experience targeted for the second half of 2027.
  • Service revenue mix and its resulting effect on gross margin.
  • PAD Aviation revenue contribution, for which full-year guidance assumes approximately $14 million.

Balance sheet and cash flow

  • Cash was $493.0 million as of September 30, 2026.
  • Cash: $492,962 (in thousands) as of September 30, 2026; $488,366 (in thousands) as of December 31, 2025.
  • Restricted cash: $18,438 (in thousands) as of September 30, 2026; $500 (in thousands) as of December 31, 2025.
  • Current portion of long-term debt, net: $54,818 (in thousands) as of September 30, 2026; $10,000 (in thousands) as of December 31, 2025.
  • Convertible senior notes, net: $454,994 (in thousands) as of September 30, 2026; $452,804 (in thousands) as of December 31, 2025.
  • Long-term debt, net: $— as of September 30, 2026; $49,587 (in thousands) as of December 31, 2025.
  • Finance lease liability: $351,533 (in thousands) as of September 30, 2026; $— as of December 31, 2025.
  • Total assets: $1,517,937 (in thousands) as of September 30, 2026; $1,068,373 (in thousands) as of December 31, 2025.
  • Total liabilities: $967,225 (in thousands) as of September 30, 2026; $595,273 (in thousands) as of December 31, 2025.
  • Total stockholders’ equity: $550,712 (in thousands) as of September 30, 2026; $473,100 (in thousands) as of December 31, 2025.

Analysis

TransMedics reported third-quarter revenue of $203.0 million, up 41% from $143.8 million. Organic revenue was $193.6 million and organic revenue growth was 34.6%. Growth reflected increasing Liver and Heart volume through the National OCS Program, additional logistics-services revenue, and PAD Aviation, which contributed $9.4 million of charter-services revenue in the quarter. Product revenue was $113.4 million, up 29%, while service revenue was $89.6 million, up 60%. The company described the quarter as its strongest in history, with record revenue and record case volume.

Revenue growth came with a modest gross-margin decline and substantially higher operating expense. Gross margin was 58.5%, compared with 58.8%, as a higher mix of service revenue weighed on margin. This was partly offset by reduced scrap, lower inventory adjustments, pricing improvements, reduced supplemental lift utilization, lower ground transportation cost per mission and fixed-cost leverage. Operating expenses rose to $90.5 million from $61.3 million, reflecting clinical and development spending for OCS Kidney, Next-Generation OCS and ENHANCE, higher headcount, headquarters-related infrastructure, and PAD Aviation.

GAAP income from operations increased 21% to $28.1 million, but operating margin declined to 13.9% from 16.2%. GAAP net income declined to $17.1 million from $24.3 million, and diluted EPS declined to $0.46 from $0.66. Adjusted income from operations rose 22% to $28.9 million, while adjusted diluted EPS declined 24% to $0.51. For the nine months ended September 30, 2026, total revenue increased 27% to $566.9 million, while GAAP operating income decreased 25% to $65.2 million and GAAP diluted EPS decreased 53% to $1.08.

The balance sheet reported $493.0 million of cash as of September 30, 2026. Convertible senior notes, net were $454,994 (in thousands), and finance lease liability was $351,533 (in thousands). The release did not report operating cash flow, free cash flow, share repurchases or dividends. The company raised FY 2026 revenue guidance including PAD Aviation to $764-$774 million, with implied annual growth of 26% to 28%, and guided to $750-$760 million excluding PAD Aviation.

The reported growth strategy centers on extending the OCS platform and building logistics capacity. During the period, TransMedics completed enrollment in ENHANCE Heart Part A, secured a continued access protocol for an additional 90 patients, received FDA IDE approvals for ENHANCE Heart Part B and DENOVO Lung, and won its first European transplant logistics tender in Italy. Management also cited planned OCS NOP launches in Italy, the Netherlands and Belgium and stated that OCS Kidney remains on track for first-in-human clinical experience in the second half of 2027. Execution against these programs, the service-revenue mix, PAD Aviation integration and margin performance are the central reported items to monitor.

Management, verbatim

The third quarter of 2026 was the strongest in TransMedics’ history, with record revenue and record case volume. Importantly, we delivered these results despite typical third quarter seasonality and before any contribution from ENHANCE Part B or DENOVO.

Waleed Hassanein, MD, President and Chief Executive Officer

We enter 2027 with strong momentum and a robust set of growth catalysts. ENHANCE Heart Part B and DENOVO Lung target large, untapped heart and lung segments, with two shots on goal in each through OCS and CHOPS.

Waleed Hassanein, MD, President and Chief Executive Officer

Not in the filing

stated, not guessed
  • Prior-quarter comparisons for reported financial metrics
  • Operating cash flow
  • Free cash flow
  • Capital expenditures
  • Share repurchases
  • Dividends
  • FY 2026 gross margin guidance
  • FY 2026 operating expense guidance
  • FY 2026 tax-rate guidance
  • The previous outlook covered the full year 2026 only, so there is nothing to compare for the third quarter.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

second quarter of 2026

AlphAI · Earnings readTMDX · second quarter of 2026 · ended June 30, 2026

TransMedics reported second-quarter total revenue of $189.9 million, up 21%, raised the low end of full-year 2026 revenue guidance, and reported lower operating income and net income.

→Mixed quarter

Revenue grew 21%, with service revenue up 29% and full-year revenue guidance raised at the low end, but gross margin declined to 60%, operating income declined 35%, and diluted net income per share declined 55%.

Revenue
$190M
21% y/y
Net product revenue
$111M
16% y/y
Gross margin · GAAP
60 %
EPS · non-GAAP
$0.44
-52 % y/y
full-year 2026 outlook
$737 million to $757 million

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenueGAAP$189.9M–21%
Net product revenueGAAP$111.2M–16%
Service revenueGAAP$78.8M–29%
Gross profitGAAP$113.2M––
Gross marginGAAP60 %––
Research, development and clinical trials expenseGAAP$31.63M––
Selling, general and administrative expenseGAAP$57.83M––
Total operating expensesGAAP$89.5M––
Stock compensation expenseGAAP$8.2M––
Income from operationsGAAP$23.7M–-35 %
Operating marginGAAP12.5 %–-1074bps
Adjusted income from operationsnon-GAAP$25.8M–-29 %
Adjusted operating marginnon-GAAP13.6 %–-960bps
Net incomeGAAP$14.7M––
Diluted net income per shareGAAP$0.41–-55 %
Basic net income per shareGAAP$ 0.42––
Adjusted net incomenon-GAAP$16.2M––
Adjusted diluted net income per sharenon-GAAP$0.44–-52 %
Six months ended June 30 total revenueGAAP$363.9M–21 %
Six months ended June 30 income from operationsGAAP$37.03M–-42 %
Six months ended June 30 net incomeGAAP$22.00M––
Six months ended June 30 diluted net income per shareGAAP$ 0.61–-62 %
Six months ended June 30 adjusted diluted net income per sharenon-GAAP$ 0.75–-55 %

Segments

SegmentRevenueq/qy/y
Net product revenueThe company cited increased utilization of the Organ Care System, primarily in Liver and Heart through the National OCS Program.$111.2M–16%
Service revenueThe company cited additional revenue generated by TransMedics logistics services.$78.8M–29%

Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.

full-year 2026 outlook

  • Revenue$737 million to $757 million
  • NoteGuidance excludes any revenue attributable to the recent strategic investment in PAD Aviation service GmbH.
  • NoteGuidance assumes no incremental revenue from the ENHANCE Part B and DENOVO clinical trials.
  • NoteGuidance represents approximately 22% to 25% growth compared to the company’s prior year revenue.

What drove it

  • Total revenue growth was driven primarily by increased OCS utilization, primarily in Liver and Heart through the NOP, and additional logistics-services revenue.
  • Service revenue grew 29%, faster than net product revenue growth of 16%.
  • The company completed its strategic investment in PAD Aviation on July 1, 2026 as a first step toward a dedicated organ transplantation air logistics network across Europe and beyond.
  • Operating-expense growth was driven primarily by planned investment in OCS Kidney, Gen 3.0 and clinical programs, together with selected infrastructure investments required to support growth.

Concerns

  • Gross margin was 60%, compared with 61% in the prior-year period. The company attributed the decrease primarily to a higher mix of service revenue and temporary product-cost factors, including inventory provisioning and trial-related solution cost, partly offset by improved logistics efficiency.
  • Income from operations was $23.7 million compared to $36.6 million, while operating margin was 12.5% compared to 23.2%.
  • Net income was $14.7 million compared to $34.9 million, and diluted net income per share was $0.41 compared to $0.92.
  • The company disclosed that it has identified a material weakness in its internal control over financial reporting.

What to watch

  • Execution of the full-year 2026 revenue guidance range of $737 million to $757 million, which excludes PAD Aviation revenue.
  • The pace of service-revenue growth and its effect on gross margin.
  • Temporary product-cost factors, including inventory provisioning and trial-related solution cost, and the extent to which improved logistics efficiency offsets them.
  • Spending on OCS Kidney, Gen 3.0, clinical programs and growth-supporting infrastructure.
  • Revenue contributions, if any, from PAD Aviation, which are excluded from the full-year 2026 revenue guidance.
  • Potential incremental revenue from the ENHANCE Part B and DENOVO clinical trials, which is not assumed in guidance.

Balance sheet and cash flow

  • Cash was $472.7 million as of June 30, 2026.
  • Cash: $ 472,675 (in thousands) as of June 30, 2026, compared with $ 488,366 (in thousands) as of December 31, 2025.
  • Convertible senior notes, net: $ 454,260 (in thousands) as of June 30, 2026, compared with $ 452,804 (in thousands) as of December 31, 2025.
  • Current portion of long-term debt: $ 20,000 (in thousands) as of June 30, 2026, compared with $ 10,000 (in thousands) as of December 31, 2025.
  • Long-term debt, net: $ 39,743 (in thousands) as of June 30, 2026, compared with $ 49,587 (in thousands) as of December 31, 2025.
  • Finance lease liability: $ 347,660 (in thousands) as of June 30, 2026.
  • No operating cash flow or free cash flow was reported in the filing.

Analysis

TransMedics delivered $189.9 million of second-quarter revenue, a 21% increase from $157.4 million in the second quarter of 2025. Growth reflected increased OCS utilization, primarily in Liver and Heart through the NOP, and additional logistics-services revenue. Service revenue grew 29% to $78.8 million, exceeding the 16% increase in net product revenue to $111.2 million. For the first six months, total revenue was $363.9 million, up 21% from $300.9 million.

The revenue mix and cost factors pressured profitability. Gross margin was 60%, compared with 61% in the prior-year period, which the company attributed primarily to a higher mix of service revenue, inventory provisioning and trial-related solution cost. Total operating expenses increased to $89.5 million from $60.0 million, led by investments in OCS Kidney, Gen 3.0, clinical programs and growth-supporting infrastructure. As a result, GAAP operating income declined to $23.7 million from $36.6 million and operating margin declined to 12.5% from 23.2%.

GAAP net income was $14.7 million, or $0.41 per diluted share, compared with $34.9 million, or $0.92 per diluted share. Adjusted income from operations was $25.8 million, compared with $36.6 million, while adjusted operating margin was 13.6%, compared with 23.2%. Adjusted net income was $16.2 million, or $0.44 per diluted share, compared with $34.9 million, or $0.92 per diluted share. The second-quarter non-GAAP adjustments consisted of transaction-related costs, headquarters relocation costs and ERP implementation costs.

The company raised the low end of its full-year 2026 revenue guidance to $737 million to $757 million from the previously reported range of $727 million to $757 million. The updated guidance excludes revenue attributable to PAD Aviation, assumes no incremental revenue from the ENHANCE Part B and DENOVO clinical trials, and represents approximately 22% to 25% growth compared to prior-year revenue. TransMedics completed its PAD Aviation strategic investment on July 1, 2026, positioning it as an additional logistics-network initiative outside the stated guidance.

Cash was $472.7 million at June 30, 2026, compared with $488.4 million at December 31, 2025. The balance sheet also reported $454.3 million of convertible senior notes, net, $20.0 million of current long-term debt, $39.7 million of long-term debt, net, and $347.7 million of finance lease liability. The filing did not report operating cash flow, free cash flow, share repurchases or dividends. The central reported tradeoff is continued revenue and service growth alongside lower gross margin and materially lower operating and net income as the company funds product, clinical, infrastructure and logistics initiatives.

Management, verbatim

The second quarter was a defining one for TransMedics: record revenue, accelerating service growth, and sequential gross margin expansion, all as we invested aggressively in our strategic priorities.

Waleed Hassanein, MD, President and Chief Executive Officer

Let me be direct about how we see our business: we are building TransMedics to remain a growth company in the near, mid, and long terms. We are deploying capital behind four distinct growth opportunities that we believe will drive substantial revenue growth with a compelling operating profile at scale.

Waleed Hassanein, MD, President and Chief Executive Officer

Not in the filing

stated, not guessed
  • Prior-quarter comparisons for revenue, product revenue, service revenue, gross margin, operating expenses, operating income, net income, and earnings per share were not reported.
  • Operating cash flow was not reported.
  • Free cash flow was not reported.
  • Share repurchases were not reported.
  • Dividends were not reported.
  • Forward guidance for gross margin, operating expenses and tax rate was not reported.
  • A separate previous-release outlook section was not provided; therefore, no reported actual-versus-prior-guidance comparison is included.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about TMDX earnings dates

When is TransMedics Group's next earnings date?
AlphAI has no date for TMDX yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.